KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvatinib) Approved In Japan For Patients With Unresectable,…
First Approval in Japan for the KEYTRUDA Plus LENVIMA Combination
Merck , known as MSD outside the United States and Canada, and Eisai announced that…